Aetna is in the process of transforming from a traditional health insurance company to becoming a healthcare-focused company, in part by emphasizing value-based reimbursement and social determinants of health, said Harold L. Paz, MD, MS, executive vice president and chief medical officer at Aetna.
Aetna is in the process of transforming from a traditional health insurance company to becoming a healthcare-focused company, in part by emphasizing value-based reimbursement and social determinants of health, said Harold L. Paz, MD, MS, executive vice president and chief medical officer at Aetna.
Transition (slightly modified)
What challenges do you foresee as Aetna continues to move toward value-based care?
For Aetna I would say the opportunity, and with that the challenge, is how we transform this company from being a traditional health insurance company to becoming a healthcare company. And that’s really our focus in our Vision 2020 strategic plan. We believe that in the future the emphasis will be on value-based reimbursement models and the need to really coordinate care for individuals that bring in the social determinants of health and the multiple determinants of health to increase the number of healthy days that each individual has. That’s not just physical health, but it’s mental health, and it’s social health.
To do that effectively, it really requires creating these innovative partnerships that begin in the home and are based in the community. That is a massive transformation for Aetna, but it is one that we’re fully committed to. It is in our vision and that’s what our entire strategic plan is predicated on.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Bimekizumab Poised to Tackle Unmet HS Treatment Needs
October 18th 2024Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
Read More